{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:34:46Z","timestamp":1794558886575,"version":"4.9.1"},"reference-count":297,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.anai.2023.11.009","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:24:02Z","timestamp":1702859042000},"page":"274-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":397,"title":["Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE\u2013 and Institute of Medicine\u2013based recommendations"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8269-4496","authenticated-orcid":false,"given":"Derek K.","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Netahe","family":"Asiniwasis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Boguniewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"De Benedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Ellison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfred T.","family":"Frazier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Greenhawt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joey","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"LeBovidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Laura","family":"Lind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peck Y.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Spergel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon H.","family":"Guyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korey","family":"Capozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy Smith","family":"Begolka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandro W.L.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene X.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Oykhman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layla","family":"Bakaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Golden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Shaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Greenhawt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline C.","family":"Horner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Stukus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Rank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elissa","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Ledford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek K.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.anai.2023.11.009_bib0001","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1016\/j.jaip.2022.06.017","article-title":"Trustworthy patient-centered guidelines: insights from atopic dermatitis and a proposal for the future","volume":"10","author":"Agarwal","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0002","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/bjd.21822","article-title":"The sound of silence: where are the voices of patients in eczema guideline development?","volume":"187","author":"Capozza","year":"2022","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0003","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/bjd.20972","article-title":"Global Guidelines in Dermatology Mapping Project (GUIDEMAP), a systematic review of atopic dermatitis clinical practice guidelines: are they clear, unbiased, trustworthy and evidence based (CUTE)?","volume":"186","author":"Arents","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2023.11.009_bib0004","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jclinepi.2023.05.010","article-title":"The development methods of official GRADE articles and requirements for claiming the use of GRADE - a statement by the GRADE guidance group","volume":"159","author":"Sch\u00fcnemann","year":"2023","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"10.1016\/j.anai.2023.11.009_bib0005","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/jamapediatrics.2022.3109","article-title":"What parents should know about atopic dermatitis","volume":"176","author":"Wheeler","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"43","key":"10.1016\/j.anai.2023.11.009_bib0006","doi-asserted-by":"crossref","first-page":"E1485","DOI":"10.1503\/cmaj.212094","article-title":"Managing atopic dermatitis in infants","volume":"194","author":"Whalen-Browne","year":"2022","journal-title":"CMAJ"},{"issue":"12","key":"10.1016\/j.anai.2023.11.009_bib0007","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1016\/j.jaip.2021.09.035","article-title":"Translating evidence to optimize Patient Care using GRADE","volume":"9","author":"Chu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"17","key":"10.1016\/j.anai.2023.11.009_bib0008","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1001\/jama.1992.03490170092032","article-title":"Evidence-based medicine. A new approach to teaching the practice of medicine","volume":"268","year":"1992","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2012.12.672","article-title":"Atopic dermatitis: a practice parameter update 2012","volume":"131","author":"Schneider","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0010","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaip.2014.02.015","article-title":"Clinical management of atopic dermatitis: practical highlights and updates from the atopic dermatitis practice parameter 2012","volume":"2","author":"Lio","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0011","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2500\/aap.2014.35.3798","article-title":"Atopic dermatitis: the updated practice parameter and beyond","volume":"35","author":"Boguniewicz","year":"2014","journal-title":"Allergy Asthma Proc"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0012","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1081-1206(10)61385-3","article-title":"Disease management of atopic dermatitis: an updated practice parameter","volume":"93","author":"Leung","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0013","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1081-1206(10)63003-7","article-title":"Disease management of atopic dermatitis: a practice parameter","volume":"79","author":"Leung","year":"1997","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0014","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jaci.2023.08.030","article-title":"Topical treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials","volume":"152","author":"Chu","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2352-4642(22)00283-8","article-title":"Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis","volume":"7","author":"Devasenapathy","year":"2023","journal-title":"The Lancet Child Adolesc Health"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0016","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.anai.2022.03.024","article-title":"Bleach baths for atopic dermatitis: a systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE","volume":"128","author":"Bakaa","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"10.1016\/j.anai.2023.11.009_bib0017","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1016\/j.jaip.2022.06.044","article-title":"Dietary elimination for the treatment of atopic dermatitis: a systematic review and meta-analysis","volume":"10","author":"Oykhman","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0018","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2022.09.020","article-title":"Allergen immunotherapy for atopic dermatitis: systematic review and meta-analysis of benefits and harms","volume":"151","author":"Yepes-Nu\u00f1ez","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0019","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","article-title":"Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials","volume":"152","author":"Chu","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0020","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamadermatol.2022.6045","article-title":"Values and preferences of patients and caregivers regarding treatment of atopic dermatitis (eczema): a systematic review","volume":"159","author":"Maleki-Yazdi","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0021","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.19580","article-title":"The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017*","volume":"184","author":"Laughter","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2023.11.009_bib0022","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0023","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jaci.2009.10.009","article-title":"Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three","volume":"124","author":"Odhiambo","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0024","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","article-title":"Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study","volume":"132","author":"Silverberg","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0025","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0026","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.jaad.2018.05.1241","article-title":"A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis","volume":"80","author":"Lee","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0027","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40257-017-0299-4","article-title":"Systematic review of diagnostic criteria used in atopic dermatitis randomized controlled trials","volume":"19","author":"Vakharia","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0028","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1365-2133.2007.08412.x","article-title":"Diagnostic criteria for atopic dermatitis: a systematic review","volume":"158","author":"Brenninkmeijer","year":"2008","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0029","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/bjd.16340","article-title":"Systematic review of atopic dermatitis disease definition in studies using routinely collected health data","volume":"178","author":"Dizon","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2023.11.009_bib0030","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/00015555924447","article-title":"Diagnostic features of atopic dermatitis","volume":"92","author":"Hanifin","year":"1980","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0031","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2133.1994.tb08530.x","article-title":"The U.K. Working Party's diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis","volume":"131","author":"Williams","year":"1994","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0032","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaci.2012.01.075","article-title":"How should an incident case of atopic dermatitis be defined? A systematic review of primary prevention studies","volume":"130","author":"Simpson","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-8561(03)00066-3","article-title":"Epidemiology of atopic dermatitis","volume":"22","author":"Larsen","year":"2002","journal-title":"Immunol Allergy Clin North Am"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0034","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/jdv.18008","article-title":"Classifying atopic dermatitis: a systematic review of phenotypes and associated characteristics","volume":"36","author":"Bosma","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0035","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1111\/ijd.14763","article-title":"Impact of atopic dermatitis on quality of life in adults: a systematic review and meta-analysis","volume":"59","author":"Birdi","year":"2020","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0036","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2133.2006.07185.x","article-title":"A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases","volume":"155","author":"Beattie","year":"2006","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0037","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.jaci.2022.03.017","article-title":"The HOME Core outcome set for clinical trials of atopic dermatitis","volume":"149","author":"Williams","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0038","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaci.2014.07.043","article-title":"The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials","volume":"134","author":"Schmitt","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0039","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","article-title":"Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults","volume":"74","author":"Simpson","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2023.11.009_bib0040","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.jaip.2021.12.012","article-title":"Burden and characteristics of skin pain among children with atopic dermatitis","volume":"10","author":"Cheng","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0041","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.anai.2017.09.076","article-title":"Burden of skin pain in atopic dermatitis","volume":"119","author":"Vakharia","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0042","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jaci.2018.08.005","article-title":"Sleep disorders and atopic dermatitis: a 2-way street?","volume":"142","author":"Chang","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0043","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2019.0025","article-title":"Association of atopic dermatitis with sleep quality in children","volume":"173","author":"Ramirez","year":"2019","journal-title":"JAMA Pediatr"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0044","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jaci.2015.08.028","article-title":"Nocturnal eczema: review of sleep and circadian rhythms in children with atopic dermatitis and future research directions","volume":"136","author":"Fishbein","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0045","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/bjhp.12467","article-title":"Psychosocial needs of adolescents and young adults with eczema: a secondary analysis of qualitative data to inform a behaviour change intervention","volume":"26","author":"Ghio","year":"2021","journal-title":"Br J Health Psychol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0046","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1111\/jdv.17943","article-title":"Impact of childhood atopic dermatitis on life decisions for caregivers and families","volume":"36","author":"Capozza","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0047","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/DER.0000000000000582","article-title":"Insights from caregivers on the impact of pediatric atopic dermatitis on families: \u201cI'm tired, overwhelmed, and feel like I'm failing as a mother","volume":"31","author":"Capozza","year":"2020","journal-title":"Dermatitis"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0048","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1001\/jamadermatol.2018.5641","article-title":"Assessment of sleep disturbances and exhaustion in mothers of children with atopic dermatitis","volume":"155","author":"Ramirez","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.anai.2023.11.009_bib0049","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jpeds.2022.04.027","article-title":"The family impact of atopic dermatitis in the pediatric population: results from an international cross-sectional study","volume":"246","author":"Barbarot","year":"2022","journal-title":"J Pediatr"},{"issue":"10247","key":"10.1016\/j.anai.2023.11.009_bib0050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"issue":"10023","key":"10.1016\/j.anai.2023.11.009_bib0051","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0052","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jaci.2022.10.023","article-title":"Novel insights into atopic dermatitis","volume":"151","author":"Schuler","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2023.11.009_bib0053","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.943640","article-title":"Atopic dermatitis: is innate or adaptive immunity in control? A clinical perspective","volume":"13","author":"Ong","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0054","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jaci.2023.01.019","article-title":"Biomarkers in atopic dermatitis","volume":"151","author":"Bakker","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2023.04.018","article-title":"Clinical aspects and management of chronic itch","volume":"152","author":"Zeidler","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0056","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jaci.2023.05.002","article-title":"Understanding neural mechanisms of mechanical itch","volume":"152","author":"Feng","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0057","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jaci.2023.05.004","article-title":"Basic mechanisms of itch","volume":"152","author":"Misery","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0058","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jaci.2023.04.006","article-title":"Neuropathic pruritus","volume":"152","author":"Kwatra","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0059","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaci.2023.05.009","article-title":"Itch in elderly patients: origin, diagnostics, management","volume":"152","author":"Steinhoff","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.alit.2021.11.006","article-title":"Skin barrier defects in atopic dermatitis: from old idea to new opportunity","volume":"71","author":"Yoshida","year":"2022","journal-title":"Allergol Int"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0061","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/genes11040442","article-title":"Genetics and epigenetics of atopic dermatitis: an updated systematic review","volume":"11","author":"Martin","year":"2020","journal-title":"Genes (Basel)"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2012.08.002","article-title":"IL-33, but not thymic stromal lymphopoietin or IL-25, is central to mite and peanut allergic sensitization","volume":"131","author":"Chu","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0063","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.anai.2020.08.002","article-title":"The infectious complications of atopic dermatitis","volume":"126","author":"Wang","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0064","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jaip.2023.01.012","article-title":"Skin antiseptics for atopic dermatitis: dissecting facts from fiction","volume":"11","author":"Ong","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0065","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jaci.2014.10.043","article-title":"Eczema is associated with osteoporosis and fractures in adults: a US population-based study","volume":"135","author":"Garg","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0066","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","article-title":"Comorbidities and the impact of atopic dermatitis","volume":"123","author":"Silverberg","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0067","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jid.2016.08.022","article-title":"Increasing comorbidities suggest that atopic dermatitis is a systemic disorder","volume":"137","author":"Brunner","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0068","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s40257-018-0383-4","article-title":"Major comorbidities of atopic dermatitis: beyond allergic disorders","volume":"19","author":"Paller","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0069","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jaci.2022.12.002","article-title":"Comorbidities of atopic dermatitis-what does the evidence say?","volume":"151","author":"Thyssen","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0070","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.anai.2018.07.042","article-title":"Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0071","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/pde.14588","article-title":"Predictors and age-dependent pattern of psychologic problems in childhood atopic dermatitis","volume":"38","author":"Hou","year":"2021","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0072","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00403-023-02536-2","article-title":"Longitudinal course of cognitive impairment in patients with atopic dermatitis","volume":"315","author":"Jackson-Cowan","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0073","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40257-019-00455-5","article-title":"Ocular co-morbidities of atopic dermatitis. Part I: associated ocular diseases","volume":"20","author":"Beck","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0074","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40257-019-00465-3","article-title":"Ocular co-morbidities of atopic dermatitis. Part II: Ocular disease secondary to treatments","volume":"20","author":"Beck","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0075","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jaad.2020.11.037","article-title":"Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: a systematic review and meta-analysis","volume":"85","author":"Ravn","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2023.11.009_bib0076","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jaip.2021.09.026","article-title":"Atopic eczema-associated fracture risk and oral corticosteroids: a population-based cohort study","volume":"10","author":"Matthewman","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0077","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaci.2019.09.015","article-title":"Atopic eczema and fracture risk in adults: a population-based cohort study","volume":"145","author":"Lowe","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2023.11.009_bib0078","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jpeds.2016.03.063","article-title":"Associations of physical activity and sedentary behavior with atopic disease in United States children","volume":"174","author":"Strom","year":"2016","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0079","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.anai.2021.09.004","article-title":"Fracture risks in patients with atopic dermatitis: a nationwide matched cohort study","volume":"127","author":"Lin","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0080","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00403-021-02240-z","article-title":"Controversial cardiovascular and hematologic comorbidities in atopic dermatitis","volume":"314","author":"Pandher","year":"2021","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"10.1016\/j.anai.2023.11.009_bib0081","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/all.12685","article-title":"Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies","volume":"70","author":"Silverberg","year":"2015","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0082","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.jaci.2018.11.030","article-title":"Atopic eczema and major cardiovascular outcomes: a systematic review and meta-analysis of population-based studies","volume":"143","author":"Ascott","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"1S","key":"10.1016\/j.anai.2023.11.009_bib0083","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1097\/DER.0000000000000715","article-title":"Financial burden of atopic dermatitis out-of-pocket health care expenses in the United States","volume":"32","author":"Smith Begolka","year":"2021","journal-title":"Dermatitis"},{"issue":"6S","key":"10.1016\/j.anai.2023.11.009_bib0084","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1097\/DER.0000000000000795","article-title":"Impact and associations of atopic dermatitis out-of-pocket health care expenses in the United States","volume":"33","author":"Chovatiya","year":"2022","journal-title":"Dermatitis"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0085","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s12325-021-02021-0","article-title":"Impact of social determinants on the burden of asthma and eczema: results from a US patient survey","volume":"39","author":"Bukstein","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.anai.2023.11.009_bib0086","unstructured":"United States Census Bureau. Census statistics highlight local population changes and Nation's racial and ethnic diversity: Press Release Number CB21-CN.55, United States government, ed. Vol. 2023. 2021-10-08; 2021:2020. Available at:https:\/\/www.census.gov\/newsroom\/press-releases\/2021\/population-changes-nations-diversity.html. Accessed December 12, 2023."},{"key":"10.1016\/j.anai.2023.11.009_bib0087","volume":"2023","year":"2023"},{"issue":"9","key":"10.1016\/j.anai.2023.11.009_bib0088","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0001060","article-title":"Use of race, ethnicity, and ancestry data in health research","volume":"2","author":"Lu","year":"2022","journal-title":"PLoS Glob Public Health"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0089","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.jaci.2021.02.034","article-title":"Health disparities in allergic and immunologic conditions in racial and ethnic underserved populations: a Work Group Report of the AAAAI Committee on the Underserved","volume":"147","author":"Davis","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0090","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jaci.2021.09.020","article-title":"Structural racism and its pathways to asthma and atopic dermatitis","volume":"148","author":"Martinez","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0091","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jaip.2020.10.030","article-title":"Disparities in asthma and allergy care: what can we do?","volume":"9","author":"Ogbogu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0092","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.jaci.2021.09.015","article-title":"Reframing racial and ethnic disparities in atopic dermatitis in Black and Latinx populations","volume":"148","author":"Croce","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2023.11.009_bib0093","doi-asserted-by":"crossref","DOI":"10.1177\/20406223211002979","article-title":"Nomenclature and clinical phenotypes of atopic dermatitis","volume":"12","author":"Girolomoni","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0094","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1525-1470.2012.01740.x","article-title":"Atopic dermatitis in African American children: addressing unmet needs of a common disease","volume":"29","author":"Vachiramon","year":"2012","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0095","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/exd.13514","article-title":"Atopic dermatitis in diverse racial and ethnic groups-variations in epidemiology, genetics, clinical presentation and treatment","volume":"27","author":"Kaufman","year":"2018","journal-title":"Exp Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0096","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1046\/j.1365-2133.2002.04965.x","article-title":"Reliance on erythema scores may mask severe atopic dermatitis in black children compared with their white counterparts","volume":"147","author":"Ben-Gashir","year":"2002","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0097","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijwd.2015.05.002","article-title":"The reliability and validity of outcome measures for atopic dermatitis in patients with pigmented skin: a grey area","volume":"1","author":"Zhao","year":"2015","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.anai.2023.11.009_bib0098","unstructured":"American College of Allergy Asthma & Immunology (ACAAI), the Allergy & Asthma Network (AAN). Eczema in Skin of Color. 2023. Available at: https:\/\/eczemainskinofcolor.org\/. Accessed January 1, 2023."},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0100","first-page":"1215","article-title":"Racial disparities in dermatology","volume":"315","author":"Narla","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0101","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamadermatol.2021.5596","article-title":"Assessment of changes in diversity in dermatology clinical trials between 2010-2015 and 2015-2020: a systematic review","volume":"158","author":"Chen","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0102","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jaad.2015.10.044","article-title":"Increasing racial and ethnic diversity in dermatology: a call to action","volume":"74","author":"Pandya","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0103","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.jaip.2020.02.022","article-title":"Endophenotypic variations of atopic dermatitis by age, race, and ethnicity","volume":"8","author":"Nomura","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.anai.2023.11.009_bib0104","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.jaip.2023.04.052","article-title":"Phenotypic and endotypic determinants of atopic dermatitis severity from the atopic dermatitis research network (ADRN) registry","volume":"11","author":"Simpson","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0105","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jaip.2023.03.041","article-title":"Managing atopic dermatitis in patients with skin of color","volume":"11","author":"Davis","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0106","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/archderm.138.5.634","article-title":"In the United States, blacks and Asian\/Pacific islanders are more likely than whites to seek medical care for atopic dermatitis","volume":"138","author":"Janumpally","year":"2002","journal-title":"Arch Dermatol"},{"issue":"8","key":"10.1016\/j.anai.2023.11.009_bib0107","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1016\/j.jaip.2023.05.014","article-title":"Racial and ethnic disparities in the treatment of patients with atopic dermatitis in the United States: a retrospective matched cohort study","volume":"11","author":"Al-Obaydi","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.anai.2023.11.009_bib0108","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/jamadermatol.2019.0597","article-title":"Racial and ethnic differences in atopic dermatitis-related school absences among US children","volume":"155","author":"Wan","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.anai.2023.11.009_bib0109","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.jid.2019.02.024","article-title":"Racial\/ethnic variation in use of ambulatory and emergency care for atopic dermatitis among US children","volume":"139","author":"Wan","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0110","first-page":"650","article-title":"Racial and ethnic disparities in access to emerging and frontline therapies in common dermatological conditions: a cross-sectional study","volume":"112","author":"Bell","year":"2020","journal-title":"J Natl Med Assoc"},{"issue":"8","key":"10.1016\/j.anai.2023.11.009_bib0111","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/jamadermatol.2019.0872","article-title":"Evaluation of barriers to telehealth programs and dermatological care for American Indian individuals in rural communities","volume":"155","author":"Morenz","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0112","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaad.2022.04.026","article-title":"Access to dermatologic care in Indigenous American communities","volume":"87","author":"Nguyen","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2023.11.009_bib0113","doi-asserted-by":"crossref","first-page":"AB133","DOI":"10.1016\/j.jaad.2019.06.498","article-title":"The epidemiology of xerosis, eczema, and skin care habits of Native Americans","volume":"81","author":"Zullo","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2023.11.009_bib0114","first-page":"1","volume":"1","year":"2018"},{"key":"10.1016\/j.anai.2023.11.009_bib0115","first-page":"26","article-title":"Atopic dermatitis and Canadian indigenous Peoples: burdens, barriers, and potential for solutions","volume":"2","author":"Asiniwasis","year":"2022","journal-title":"Can Allergy Immunol Today"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0116","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1525\/aeq.2005.36.1.008","article-title":"Indigenous knowledge systems and Alaska native ways of knowing","volume":"36","author":"Barnhardt","year":"2005","journal-title":"Anthropol Educ Q"},{"key":"10.1016\/j.anai.2023.11.009_bib0117","series-title":"Tribal Coll J Am Indian Higher Educ","first-page":"33","author":"Tsosie","year":"2022"},{"issue":"S2","key":"10.1016\/j.anai.2023.11.009_bib0118","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/pde.14759","article-title":"Atopic dermatitis and skin infections are a poorly documented crisis in Canada's Indigenous pediatric population: it's time to start the conversation","volume":"38","author":"Asiniwasis","year":"2021","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0119","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMp2201180","article-title":"Tackling implicit bias in health care","volume":"387","author":"Sabin","year":"2022","journal-title":"N Engl J Med"},{"issue":"10171","key":"10.1016\/j.anai.2023.11.009_bib0120","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0140-6736(18)32267-0","article-title":"The good, the bad, and the ugly of implicit bias","volume":"393","author":"Pritlove","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0121","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.anai.2022.12.017","article-title":"Proposed solutions by the American College of Allergy, Asthma, and Immunology and advocacy experts to address racial disparities in atopic dermatitis and food allergy","volume":"130","author":"Corbett","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7650","key":"10.1016\/j.anai.2023.11.009_bib0122","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0123","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/bmjebm-2022-111962","article-title":"Good or best practice statements: proposal for the operationalisation and implementation of GRADE guidance","volume":"28","author":"Dewidar","year":"2023","journal-title":"BMJ Evid Based Med"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0124","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1503\/cmaj.131237","article-title":"Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise","volume":"186","author":"Sch\u00fcnemann","year":"2014","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0125","doi-asserted-by":"crossref","first-page":"128","DOI":"10.7326\/M16-1565","article-title":"A reporting tool for practice guidelines in health care: the RIGHT statement","volume":"166","author":"Chen","year":"2016","journal-title":"Ann Intern Med"},{"issue":"18","key":"10.1016\/j.anai.2023.11.009_bib0126","doi-asserted-by":"crossref","first-page":"E839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"CMAJ"},{"key":"10.1016\/j.anai.2023.11.009_bib0127","series-title":"Clinical Practice Guidelines We Can Trust","article-title":"Developing Trustworthy Clinical Practice Guidelines","author":"Graham","year":"2011"},{"issue":"7","key":"10.1016\/j.anai.2023.11.009_bib0128","doi-asserted-by":"crossref","first-page":"548","DOI":"10.7326\/M14-1885","article-title":"Principles for disclosure of interests and management of conflicts in guidelines","volume":"163","author":"Sch\u00fcnemann","year":"2015","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0129","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0130","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jaci.2013.07.008","article-title":"Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation","volume":"132","author":"Schmitt","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0131","doi-asserted-by":"crossref","first-page":"e13609","DOI":"10.1111\/pai.13609","article-title":"Method's corner: allergist's guide to network meta-analysis","volume":"33","author":"Chu","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.anai.2023.11.009_bib0132","doi-asserted-by":"crossref","first-page":"i2016","DOI":"10.1136\/bmj.i2016","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.anai.2023.11.009_bib0133","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jclinepi.2023.06.010","article-title":"Grading of recommendations assessment, development, and evaluation concept article 5: addressing intransitivity in a network meta-analysis","volume":"160","author":"Brignardello-Petersen","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.anai.2023.11.009_bib0134","article-title":"Brignardello-Petersen R. A guide and pragmatic considerations for applying GRADE to network meta-analysis","volume":"381","author":"Izcovich","year":"2023","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0135","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/bmjebm-2021-111866","article-title":"Which actionable statements qualify as good practice statements in Covid-19 guidelines? A systematic appraisal","volume":"27","author":"Dewidar","year":"2022","journal-title":"BMJ Evid-Based Med"},{"key":"10.1016\/j.anai.2023.11.009_bib0136","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jclinepi.2021.09.028","article-title":"A taxonomy and framework for identifying and developing actionable statements in guidelines suggests avoiding informal recommendations","volume":"141","author":"Lotfi","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0137","article-title":"Emollients and moisturisers for eczema","volume":"2","author":"van Zuuren","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0138","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/bjd.15641","article-title":"Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis","volume":"177","author":"Chopra","year":"2017","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0139","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/bjd.12590","article-title":"Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods","volume":"169","author":"Charman","year":"2013","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0140","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/bjd.16078","article-title":"Severity strata for five patient-reported outcomes in adults with atopic dermatitis","volume":"178","author":"Vakharia","year":"2018","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0141","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/bjd.12437","article-title":"Clinical experience and psychometric properties of the Children's Dermatology Life Quality Index (CDLQI), 1995-2012","volume":"169","author":"Salek","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0142","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/bjd.17028","article-title":"What do scores mean? Informed interpretation and clinical judgement are needed","volume":"179","author":"Finlay","year":"2018","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0143","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jaad.2015.09.062","article-title":"A systematic review of investigator global assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards","volume":"74","author":"Futamura","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0144","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000472711","article-title":"Assessment of intra- and inter-rater reliability of three methods for measuring atopic dermatitis severity: EASI, objective SCORAD, and IGA","volume":"233","author":"Bo\u017cek","year":"2017","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0145","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.clindermatol.2018.05.012","article-title":"Assessing the severity of atopic dermatitis in clinical trials and practice","volume":"36","author":"Chopra","year":"2018","journal-title":"Clin Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0146","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jaad.2020.04.104","article-title":"The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis","volume":"83","author":"Simpson","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0147","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.20872","article-title":"IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis","volume":"186","author":"Paller","year":"2022","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0148","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000245677","article-title":"Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis","volume":"195","author":"Kunz","year":"2009","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0149","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: what do dermatology life quality index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.anai.2023.11.009_bib0150","first-page":"121","article-title":"Severity stratification of Children\u2019s Dermatology Life Quality Index (CDLQI) scores","volume":"163","author":"Waters","year":"2010","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.anai.2023.11.009_bib0151","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2352-4642(22)00146-8","article-title":"Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema: a pragmatic, randomised, phase 4, superiority trial","volume":"6","author":"Ridd","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"issue":"11","key":"10.1016\/j.anai.2023.11.009_bib0152","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamadermatol.2017.3046","article-title":"Consumer preferences, product characteristics, and potentially allergenic ingredients in best-selling moisturizers","volume":"153","author":"Xu","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.anai.2023.11.009_bib0153","doi-asserted-by":"crossref","first-page":"l5882","DOI":"10.1136\/bmj.l5882","article-title":"Which emollients are effective and acceptable for eczema in children?","volume":"367","author":"Ridd","year":"2019","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.anai.2023.11.009_bib0154","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00403-020-02060-7","article-title":"Efficacy of health education on treatment of children with atopic dermatitis: a meta-analysis of randomized controlled trials","volume":"312","author":"Li","year":"2020","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0155","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/hex.12643","article-title":"Written action plans for children with long-term conditions: a systematic review and synthesis of qualitative data","volume":"21","author":"Waldecker","year":"2018","journal-title":"Health Expect"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0156","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archdermatol.2011.2267","article-title":"Parental response to written eczema action plans in children with eczema","volume":"148","author":"Rork","year":"2012","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0157","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3109\/09546630903386598","article-title":"Physicians\u2019 perceptions of an eczema action plan for atopic dermatitis","volume":"21","author":"Ntuen","year":"2010","journal-title":"J Dermatol Treat"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0158","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1002\/ski2.213","article-title":"Where and how have written action plans for atopic eczema\/dermatitis been developed and evaluated? Systematic review","volume":"3","author":"Thandi","year":"2023","journal-title":"Skin Health Dis"},{"issue":"10","key":"10.1016\/j.anai.2023.11.009_bib0159","doi-asserted-by":"crossref","first-page":"950","DOI":"10.36849\/JDD.2020.5090","article-title":"Development and evaluation of an atopic dermatitis care plan for providers","volume":"19","author":"Utley","year":"2020","journal-title":"J Drugs Dermatol"},{"issue":"14","key":"10.1016\/j.anai.2023.11.009_bib0160","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1177\/0009922818795906","article-title":"Does an eczema action plan improve atopic dermatitis? A single-site randomized controlled trial","volume":"57","author":"Brown","year":"2018","journal-title":"Clin Pediatr (Phila)"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0161","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamadermatol.2013.2143","article-title":"Improving patient education with an eczema action plan: a randomized controlled trial","volume":"149","author":"Shi","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.anai.2023.11.009_bib0162","article-title":"Eczema Care Online behavioural interventions to support self-care for children and young people: two independent, pragmatic, randomised controlled trials","volume":"379","author":"Santer","year":"2022","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0163","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jaci.2013.12.1079","article-title":"Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful?","volume":"133","author":"Tang","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0164","article-title":"Strategies for using topical corticosteroids in children and adults with eczema","volume":"3","author":"Lax","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.anai.2023.11.009_bib0165","volume":"2023","year":"2023"},{"key":"10.1016\/j.anai.2023.11.009_bib0166","volume":"2023","year":"2023"},{"key":"10.1016\/j.anai.2023.11.009_bib0167","unstructured":"Goldstein B, Goldstein A. Topical corticosteroids: use and adverse effects. In: Waltham, MA, ed. UpToDate: UpToDate Inc."},{"issue":"12","key":"10.1016\/j.anai.2023.11.009_bib0168","first-page":"1093","article-title":"Topical corticosteroids in dermatology","volume":"8","author":"Tadicherla","year":"2009","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"10.1016\/j.anai.2023.11.009_bib0169","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2022.3774","article-title":"Reevaluating corticosteroid classification models in patient patch testing","volume":"158","author":"Chen","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"13","key":"10.1016\/j.anai.2023.11.009_bib0170","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/jama.2020.11192","article-title":"Drugs for atopic dermatitis","volume":"325","year":"2021","journal-title":"JAMA"},{"issue":"1600","key":"10.1016\/j.anai.2023.11.009_bib0171","first-page":"89","article-title":"Drugs for atopic dermatitis","volume":"62","year":"2020","journal-title":"Med Lett Drugs Ther"},{"issue":"12","key":"10.1016\/j.anai.2023.11.009_bib0172","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1016\/j.jaip.2022.08.033","article-title":"Boxed warnings and off-label use of allergy medications: risks, benefits, and shared decision making","volume":"10","author":"Greiwe","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0173","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.jaad.2020.03.074","article-title":"Framing atopic dermatitis topical medication application site discomfort as a signal of efficacy improves willingness to continue use","volume":"83","author":"Bashyam","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0174","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaip.2014.04.009","article-title":"Wet wrap therapy in children with moderate to severe atopic dermatitis in a multidisciplinary treatment program","volume":"2","author":"Nicol","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0175","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.iac.2016.08.003","article-title":"Wet wrap therapy in moderate to severe atopic dermatitis","volume":"37","author":"Nicol","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.anai.2023.11.009_bib0176","volume":"2023","year":"2017"},{"issue":"10352","key":"10.1016\/j.anai.2023.11.009_bib0177","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(22)01438-6","article-title":"The global burden of cancer attributable to risk factors, 2010\u201319: a systematic analysis for the Global Burden of Disease Study 2019","volume":"400","author":"Tran","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2023.11.009_bib0178","unstructured":"National Cancer Institute. Cancer in Children and Adolescents. Vol. 2023: NIH National Cancer Institute; 2021."},{"issue":"22","key":"10.1016\/j.anai.2023.11.009_bib0179","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients","volume":"2","author":"Sch\u00fcnemann","year":"2018","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.anai.2023.11.009_bib0180","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics\u20142022 update: a report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.anai.2023.11.009_bib0181","article-title":"Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs: nationwide cohort study","volume":"382","author":"Meaidi","year":"2023","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0182","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","article-title":"Long-term safety and disease control with Ruxolitinib cream in atopic dermatitis: results from two phase 3 studies","volume":"88","author":"Papp","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0183","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40257-021-00610-x","article-title":"Pharmacokinetics of Ruxolitinib in patients with atopic dermatitis treated with Ruxolitinib cream: data from Phase II and III studies","volume":"22","author":"Gong","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0184","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-022-00690-3","article-title":"A maximum-use trial of Ruxolitinib cream in adolescents and adults with atopic dermatitis","volume":"23","author":"Bissonnette","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0185","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.anai.2022.12.033","article-title":"Safety, pharmacokinetics, and efficacy of Ruxolitinib cream in children and adolescents with atopic dermatitis","volume":"130","author":"Leung","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2023.11.009_bib0186","article-title":"Guidelines should consider clinicians\u2019 time needed to treat","volume":"380","author":"Johansson","year":"2023","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0187","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0188","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1370\/afm.2038","article-title":"Oral and topical antibiotics for clinically infected eczema in children: a pragmatic randomized controlled trial in ambulatory care","volume":"15","author":"Francis","year":"2017","journal-title":"Ann Fam Med"},{"issue":"19","key":"10.1016\/j.anai.2023.11.009_bib0189","doi-asserted-by":"crossref","DOI":"10.3310\/hta20190","article-title":"A randomised placebo-controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, antibiotic Management (CREAM) study","volume":"20","author":"Francis","year":"2016","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.anai.2023.11.009_bib0190","first-page":"234","article-title":"Role of bacterial flora in the pathogenesis & management of atopic dermatitis","volume":"95","author":"Dhar","year":"1992","journal-title":"Indian J Med Res"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0191","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1067\/mai.2001.118598","article-title":"Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis","volume":"108","author":"Boguniewicz","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0192","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1046\/j.1365-2133.1998.02271.x","article-title":"Flucloxacillin in the treatment of atopic dermatitis","volume":"138","author":"Ewing","year":"1998","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.anai.2023.11.009_bib0193","article-title":"Interventions to reduce Staphylococcus aureus in the management of eczema","volume":"2019","author":"George","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0194","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaip.2015.02.009","article-title":"Contact dermatitis: a practice parameter-update 2015","volume":"3","author":"Fonacier","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0195","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/DER.0000000000000777","article-title":"Patch test reactions associated with topical medications: A retrospective analysis of the North American contact dermatitis group data (2001-2018)","volume":"33","author":"Warshaw","year":"2022","journal-title":"Dermatitis"},{"key":"10.1016\/j.anai.2023.11.009_bib0196","volume":"2023","year":"2021"},{"key":"10.1016\/j.anai.2023.11.009_bib0197","volume":"2023","year":"2022"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0198","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1542\/peds.2008-2217","article-title":"Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity","volume":"123","author":"Huang","year":"2009","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0199","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.jaci.2019.01.009","article-title":"Dilute bleach baths used for treatment of atopic dermatitis are not antimicrobial in vitro","volume":"143","author":"Sawada","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0200","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaci.2020.11.033","article-title":"Age and eczema severity, but not family history, are major risk factors for peanut allergy in infancy","volume":"147","author":"Keet","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"14","key":"10.1016\/j.anai.2023.11.009_bib0201","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198604033141406","article-title":"Determining optimal therapy\u2013randomized trials in individual patients","volume":"314","author":"Guyatt","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2023.11.009_bib0202","first-page":"497","article-title":"A clinician's guide for conducting randomized trials in individual patients","volume":"139","author":"Guyatt","year":"1988","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0203","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0091-6749(99)70395-7","article-title":"Birch pollen-related foods trigger atopic dermatitis in patients with specific cutaneous T-cell responses to birch pollen antigens","volume":"104","author":"Reekers","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2023.11.009_bib0204","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0091-6749(97)81053-6","article-title":"Milk-responsive atopic dermatitis is associated with a casein-specific lymphocyte response in adolescent and adult patients","volume":"99","author":"Werfel","year":"1997","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0205","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1172\/JCI117743","article-title":"Milk-induced eczema is associated with the expansion of T cells expressing cutaneous lymphocyte antigen","volume":"95","author":"Abernathy-Carver","year":"1995","journal-title":"J Clin Invest"},{"issue":"528-530","key":"10.1016\/j.anai.2023.11.009_bib0206","first-page":"e521","article-title":"Non-IgE-mediated chronic allergic skin inflammation revealed with rBet v 1 fragments","volume":"121","author":"Campana","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0207","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.iac.2006.02.004","article-title":"IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy","volume":"26","author":"Wilcock","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0208","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2010.09.034","article-title":"Allergen immunotherapy: a practice parameter third update","volume":"127","author":"Cox","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0209","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.anai.2010.04.008","article-title":"Surveillance of systemic reactions to subcutaneous immunotherapy injections: year 1 outcomes of the ACAAI and AAAAI collaborative study","volume":"104","author":"Bernstein","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0210","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.anai.2011.05.020","article-title":"Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI\/AAAAI surveillance study of subcutaneous immunotherapy: year 2","volume":"107","author":"Epstein","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0211","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2013.01.015","article-title":"AAAAI and ACAAI surveillance study of subcutaneous immunotherapy, Year 3: what practices modify the risk of systemic reactions?","volume":"110","author":"Epstein","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0212","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaip.2014.01.004","article-title":"AAAAI\/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions","volume":"2","author":"Epstein","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2023.11.009_bib0213","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.jaip.2019.01.058","article-title":"AAAAI\/ACAAI subcutaneous immunotherapy surveillance study (2013-2017): fatalities, infections, delayed reactions, and use of epinephrine autoinjectors","volume":"7","author":"Epstein","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0214","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2500\/aap.2020.41.200001","article-title":"Safety of allergen immunotherapy in North America from 2008-2017: lessons learned from the ACAAI\/AAAAI National Surveillance Study of adverse reactions to allergen immunotherapy","volume":"41","author":"Bernstein","year":"2020","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0215","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/j.jaci.2021.11.026","article-title":"Macrophages acquire a TNF-dependent inflammatory memory in allergic asthma","volume":"149","author":"Lechner","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0216","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.jaci.2022.02.014","article-title":"How are airborne allergens remembered by the immune system?","volume":"149","author":"Kita","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0217","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jaci.2018.05.027","article-title":"Emerging roles of the protease allergen Der p 1 in house dust mite-induced airway inflammation","volume":"142","author":"Chevigne","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0218","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2011.11.024","article-title":"Protease-activated receptor 2-dependent fluid secretion from airway submucosal glands by house dust mite extract","volume":"129","author":"Cho","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl 1","key":"10.1016\/j.anai.2023.11.009_bib0219","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000327492","article-title":"Protease-mediated house dust mite allergen-induced reactive oxygen species production by neutrophils","volume":"155","author":"Fukunaga","year":"2011","journal-title":"Int Arch Allergy Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0220","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nm.1946","article-title":"House dust mite allergen induces asthma via toll-like receptor 4 triggering of airway structural cells","volume":"15","author":"Hammad","year":"2009","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0221","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125983","article-title":"House dust mite allergen regulates constitutive apoptosis of normal and asthmatic neutrophils via toll-like receptor 4","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0222","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jaci.2020.10.006","article-title":"Dual function of Langerhans cells in skin TSLP-promoted TFH differentiation in mouse atopic dermatitis","volume":"147","author":"Marschall","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.anai.2023.11.009_bib0223","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/jdv.13679","article-title":"TSLP, IL-31, IL-33 and sST2 are new biomarkers in endophenotypic profiling of adult and childhood atopic dermatitis","volume":"30","author":"Nygaard","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.anai.2023.11.009_bib0224","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00105-021-04909-y","article-title":"Allergen immunotherapy for atopic dermatitis","volume":"72","author":"Traidl","year":"2021","journal-title":"Hautarzt"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0225","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jaci.2017.10.010","article-title":"Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers","volume":"140","author":"Shamji","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl 26","key":"10.1016\/j.anai.2023.11.009_bib0226","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/pai.13390","article-title":"Allergen immunotherapy in atopic dermatitis: light and shadow in children","volume":"31","author":"Caminiti","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0227","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.immuni.2020.12.013","article-title":"Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response","volume":"54","author":"Golebski","year":"2021","journal-title":"Immunity"},{"issue":"suppl 3","key":"10.1016\/j.anai.2023.11.009_bib0228","first-page":"417","article-title":"Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years","volume":"188","author":"Beck","year":"2023","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0229","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","article-title":"Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis","volume":"23","author":"Beck","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0230","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0231","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jaci.2022.10.026","article-title":"The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis","volume":"151","author":"Rank","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0232","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40268-019-00288-x","article-title":"A clinician's guide to the recognition and management of dupilumab-associated conjunctivitis","volume":"19","author":"Agnihotri","year":"2019","journal-title":"Drugs R D"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0233","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/16506073.2016.1157204","article-title":"Exposure-based Interventions for the management of individuals with high levels of needle fear across the lifespan: a clinical practice guideline and call for further research","volume":"45","author":"McMurtry","year":"2016","journal-title":"Cogn Behav Ther"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0234","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0235","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard-2022-223050","article-title":"Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis","volume":"82","author":"Molander","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0236","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"issue":"1673","key":"10.1016\/j.anai.2023.11.009_bib0237","doi-asserted-by":"crossref","first-page":"51","DOI":"10.58347\/tml.2023.1673b","article-title":"Three drugs for atopic dermatitis (Adbry, Cibinqo, and Rinvoq)","volume":"65","year":"2023","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.anai.2023.11.009_bib0238","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"9103","key":"10.1016\/j.anai.2023.11.009_bib0239","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(97)08496-1","article-title":"Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens","volume":"351","author":"Dantal","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0240","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000018065","article-title":"Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis. A double-blind, single-centre, cross-over pilot study","volume":"198","author":"Zurbriggen","year":"1999","journal-title":"Dermatology"},{"issue":"9","key":"10.1016\/j.anai.2023.11.009_bib0241","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/j.1552-4604.1995.tb04131.x","article-title":"Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis","volume":"35","author":"Elder","year":"1995","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.anai.2023.11.009_bib0242","first-page":"556","article-title":"Conversion of patients with rheumatoid arthritis from the conventional to a microemulsion formulation of cyclosporine: a double blind comparison to screen for differences in safety, efficacy, and pharmacokinetics","volume":"26","author":"Anderson","year":"1999","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0243","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/rheumatology\/39.2.156","article-title":"Microemulsion formulation of cyclosporin (Sandimmun Neoral) vs Sandimmun: comparative safety, tolerability and efficacy in severe active rheumatoid arthritis. On behalf of the OLR 302 Study Group","volume":"39","author":"Yocum","year":"2000","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.anai.2023.11.009_bib0244","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1097\/00007890-199812270-00011","article-title":"Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre international study in liver transplantation of neoral","volume":"66","author":"Otto","year":"1998","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0245","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1046\/j.1523-1755.1998.00042.x","article-title":"Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun neoral study group","volume":"54","author":"Keown","year":"1998","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.anai.2023.11.009_bib0246","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/00007890-199806150-00008","article-title":"Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun neoral study group","volume":"65","author":"Frei","year":"1998","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0247","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1046\/j.1523-1755.1999.00599.x","article-title":"Safety of Neoral conversion in maintenance renal transplant patients: a one-year, double-blind study. Novartis OLN-353 study group","volume":"56","author":"Brennan","year":"1999","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.anai.2023.11.009_bib0248","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/00007890-199911150-00018","article-title":"Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. neoral renal study group","volume":"68","author":"Pollard","year":"1999","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0249","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1432-2277.2005.00078.x","article-title":"Generic cyclosporine formulations: more open questions than answers","volume":"18","author":"Cattaneo","year":"2005","journal-title":"Transpl Int"},{"key":"10.1016\/j.anai.2023.11.009_bib0250","first-page":"240","article-title":"The efficacy, tolerability and safety of a new oral formulation of Sandimmun\u2013Sandimmun Neoral in severe refractory atopic dermatitis","volume":"11","author":"Atakan","year":"1998","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.anai.2023.11.009_bib0251","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2133.1996.tb00703.x","article-title":"Comparison of the steady state pharmacokinetics of two formulations of cyclosporin in patients with atopic dermatitis*","volume":"135","author":"Chawla","year":"1996","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0252","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1365-2133.1996.tb06990.x","article-title":"A new microemulsion formulation of cyclosporin (Neoral) is effective in the treatment of cyclosporin-resistant dermatoses","volume":"134","author":"Bourke","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2023.11.009_bib0253","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2133.1997.tb08751.x","article-title":"Comparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis","volume":"136","author":"Erkko","year":"1997","journal-title":"Br J Dermatol"},{"issue":"suppl 48","key":"10.1016\/j.anai.2023.11.009_bib0254","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2133.1996.tb00708.x","article-title":"Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporin","volume":"135","author":"Gulliver","year":"1996","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.anai.2023.11.009_bib0255","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0256","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/bjd.15377","article-title":"Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"177","author":"Mazaud","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2023.11.009_bib0257","article-title":"Phototherapy for atopic eczema","volume":"10","author":"Musters","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0258","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jaad.2015.11.041","article-title":"Distance of travel to phototherapy is associated with early nonadherence: a retrospective cohort study","volume":"74","author":"Weng","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2023.11.009_bib0259","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"issue":"155","key":"10.1016\/j.anai.2023.11.009_bib0260","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0151-2019","article-title":"Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety","volume":"29","author":"Price","year":"2020","journal-title":"Eur Respir Rev"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0261","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0262","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170259","article-title":"Systematic review of the toxicity of long-course oral corticosteroids in children","volume":"12","author":"Aljebab","year":"2017","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.anai.2023.11.009_bib0263","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0264","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jaad.2019.07.105","article-title":"Treatment patterns of pediatric patients with atopic dermatitis: a claims data analysis","volume":"82","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0265","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0266","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0267","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0268","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","article-title":"Structural Characterisation Reveals Mechanism of IL-13-Neutralising monoclonal antibody tralokinumab as Inhibition of Binding to IL-13R alpha 1 and IL-13R alpha 2","volume":"429","author":"Popovic","year":"2017","journal-title":"J Mol Biol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0269","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0270","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaci.2016.06.033","article-title":"Interleukins (from IL-1 to IL-38), interferons, transforming growth factor beta, and TNF-alpha: receptors, functions, and roles in diseases","volume":"138","author":"Akdis","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2023.11.009_bib0271","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-8-5","article-title":"Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib","volume":"9","author":"Nezamololama","year":"2020","journal-title":"Drugs Context"},{"issue":"4900","key":"10.1016\/j.anai.2023.11.009_bib0272","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1126\/science.2649979","article-title":"The purine path to chemotherapy","volume":"244","author":"Elion","year":"1989","journal-title":"Science"},{"issue":"2-3","key":"10.1016\/j.anai.2023.11.009_bib0273","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0274","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.jaci.2014.03.003","article-title":"Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology","volume":"133","author":"Khattri","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0275","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0276","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1529-8019.2007.00136.x","article-title":"Mycophenolate mofetil","volume":"20","author":"Zwerner","year":"2007","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0277","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/tri.12554","article-title":"Mycophenolate revisited","volume":"28","author":"van Gelder","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.anai.2023.11.009_bib0278","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1177\/096120330501400102","article-title":"Mechanisms of action of mycophenolate mofetil","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0279","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2011.05.042","article-title":"Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response","volume":"128","author":"Tintle","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2023.11.009_bib0280","series-title":"Therapy of skin diseases: a worldwide perspective on therapeutic approaches and their molecular basis","first-page":"87","article-title":"Ultraviolet (UV) A and (UV) B phototherapy","author":"Morita","year":"2010"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0281","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40257-016-0209-1","article-title":"Complementary and alternative medicine for atopic dermatitis: an evidence-based review","volume":"17","author":"Vieira","year":"2016","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2023.11.009_bib0282","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jid.2016.09.037","article-title":"An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease","volume":"137","author":"Ungar","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0283","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2022.100131","article-title":"Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis","volume":"2","author":"Beck","year":"2022","journal-title":"JID Innov"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0284","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/bjd.18938","article-title":"Racial and ethnic disparities in global atopic dermatitis clinical trials","volume":"183","author":"Price","year":"2020","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.anai.2023.11.009_bib0285","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1080\/09546634.2022.2114783","article-title":"Racial and ethnic diversity of US participants in clinical trials for acne, atopic dermatitis, and psoriasis: a comprehensive review","volume":"33","author":"Sevagamoorthy","year":"2022","journal-title":"J Dermatol Treat"},{"issue":"2","key":"10.1016\/j.anai.2023.11.009_bib0286","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjd.20740","article-title":"Underreporting of race and ethnicity in paediatric atopic dermatitis clinical trials: a cross-sectional analysis of demographic reporting and representation","volume":"186","author":"Ding","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2023.11.009_bib0287","unstructured":"The Journal of Allergy and Clinical Immunology. Practice. Reporting race and ethnicity. 2023. Available at: https:\/\/www.jaci-inpractice.org\/guidelines-reporting-race-ethnicity. Accessed May 1, 2023."},{"key":"10.1016\/j.anai.2023.11.009_bib0288","unstructured":"Global Initiative for Asthma. 2023 GINA Report, Global Strategy for Asthma Management and Prevention. 2023. Available at: https:\/\/ginasthma.org\/2023-gina-main-report\/. Accessed December 12, 2023."},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0289","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jaci.2020.01.017","article-title":"Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis","volume":"145","author":"Shaker","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2023.11.009_bib0290","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.anai.2020.03.009","article-title":"Joint Task Force for Allergy Practice Parameters, et al. Making the GRADE in anaphylaxis management: toward recommendations integrating values, preferences, context, and shared decision making","volume":"124","author":"Shaker","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2023.11.009_bib0291","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.anai.2020.03.020","article-title":"AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis","volume":"124","author":"Hirano","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0292","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jaci.2020.07.031","article-title":"Peanut allergy diagnosis: A 2020 practice parameter update, systematic review, and GRADE analysis","volume":"146","author":"Greenhawt","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.11.009_bib0293","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jaci.2020.07.007","article-title":"Rhinitis 2020: a practice parameter update","volume":"146","author":"Dykewicz","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.11.009_bib0294","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2017.10.039","article-title":"Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape","volume":"120","author":"Boguniewicz","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.11.009_bib0295","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.anai.2023.03.010","article-title":"Atopic Dermatitis Yardstick update","volume":"130","author":"Boguniewicz","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2023.11.009_bib0296","unstructured":"European Dermatology Forum. Living EuroGuiDerm Guideline for the systemic treatment of Atopic Eczema. 2023. Available at: https:\/\/www.guidelines.edf.one\/guidelines\/atopic-ezcema. Accessed December 12, 2023."},{"issue":"10","key":"10.1016\/j.anai.2023.11.009_bib0297","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1016\/j.jaip.2023.07.046","article-title":"Answering the call for trustworthy clinical guidelines","volume":"11","author":"Shaker","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2023.11.009_bib0298","doi-asserted-by":"crossref","first-page":"n1531","DOI":"10.1136\/bmj.n1531","article-title":"Just another eczema case for you, but to me it's the world","volume":"374","author":"Fong","year":"2021","journal-title":"BMJ"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120623014552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120623014552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:34:38Z","timestamp":1761053678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120623014552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":297,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1081120623014552"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2023.11.009","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE\u2013 and Institute of Medicine\u2013based recommendations","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2023.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}